Back to top
more

GlycoMimetics (GLYC)

(Delayed Data from NSDQ)

$1.84 USD

1.84
1,218,135

-0.12 (-6.14%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $1.84 +0.01 (0.27%) 6:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for GLYC

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

GlycoMimetics, Inc. [GLYC]

Reports for Purchase

Showing records 61 - 80 ( 156 total )

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 61

04/09/2021

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 62

03/11/2021

Industry Report

Pages: 3

Our Covered Companies Will Present at AACR

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 63

03/03/2021

Daily Note

Pages: 4

Healthcare- Please Join Our Virtual 33rd Annual ROTH Conference on March 15 - 17th

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 64

03/03/2021

Company Report

Pages: 8

4Q20 Results; Uproleselan Pivotal Trial Enrollment Expected to be Reached in 2H21; Lower PT by $1

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 65

03/02/2021

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 66

03/02/2021

Company Report

Pages: 6

4Q20 Update - Liking the Focus, GLYC Remains One of Our Undervalued Gems

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 67

01/08/2021

Daily Note

Pages: 4

MORNING & MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 68

01/07/2021

Daily Note

Pages: 3

Uproleselan Granted Breakthrough Therapy Designation in China for AML

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 69

01/07/2021

Company Report

Pages: 5

GLYC & Apollomics Announce Uproleselan''s BTD for r/r AML in China

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 70

12/08/2020

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 71

12/08/2020

Company Report

Pages: 7

New OLE Results for Rivipansel in the Acute Treatment of Vaso-occlusive Crisis at ASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 72

12/07/2020

Company Report

Pages: 8

ASH Highlights Game-Changing AML & Sickle Cell Data. Raising PT to $15.

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 73

11/10/2020

Company Report

Pages: 5

Ahead of ASH, Dial into Our Sickle Cell KOL Call Tomorrow at 12PM ET

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 74

11/10/2020

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 75

11/09/2020

Company Report

Pages: 8

3Q20 Results; Phase 3 r/r AML Trial on Track; Multiple Data Presentations Expected at ASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 76

11/06/2020

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 77

11/06/2020

Company Report

Pages: 6

3Q20 Update - Multiple Shots on Goal With Momentum Set to Build at ASH

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 78

11/02/2020

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 79

10/30/2020

Company Report

Pages: 6

Two Solid Shots on Goal for Treating Acute VOC Due to Sickle Cell

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 80

10/27/2020

Company Report

Pages: 7

Rivipansel Phase 3 Presentation and GMI-1687 Preclinical Data Oral Presentation at ASCAT

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party